Ritu Baral: Hi guys. Thanks for taking the questions. Apologies for the poor connection. Sath, I wanted to ask you about the decision to include some subsection of refractory patients in the Phase 2. Can you talk to how it will – how it may impact top line data and whether you expect the two groups to behave differently on the primary endpoint? And if there is a way to sort of tease apart any differences to tell you what you need for Phase 3.
Sath Shukla: Yes. I think for the trial design, let me defer to Kamal to speak to it for a little bit, and I think then I can stay in on the top line data. Kamal, would you care to provide an opinion?
Kamal Hamed: Sure. Thank you, Ritu, for the question. So, as Sath indicated, Spero has strategically – strategically pursuing development for first-line treatment. So, first-line treatment, that means patients for treatment naïve or treatment experienced, but do not have refractory disease. And again, that’s about 17% odd of the patient population. So, the current study is in treatment naïve or treatment experience, but patients who do not have refractory disease. So, this is the development path that Spero is currently pursuing. So, in this particular study, Ritu, there is no refractory disease patients who will be enrolled. As a matter of fact, they are being excluded from the study. And as a reminder, the study is a proof-of-concept study composed of about up to 35 patients.
Ritu Baral: So, there is a distinction between relapsed and refractory. And you believe that the disease course or at least the infectious burden and the ability to clear infection is different between the two populations?
Sath Shukla: It’s not that the ability to clear the infection using the drug is necessarily different. Just as a reminder, SPR720 is a novel drug and has no cross-resistance with other antibiotics, and we do not expect that in the clinic – we expect that it would work in the clinic for the factory disease patients. However, this strategy has been to pursue first-line treatment as the first path for development. So, given that this is our development path, so the study will enroll patients who do not have refractory disease. The only treatment naïve patients or patients who are treatment experience, but again are not considered to have refractory disease.
Ritu Baral: Okay. Thanks.
Sath Shukla: And we have not disclosed development beyond this current Phase 2a proof-of-concept study. But again, not to say that there would be a concern that SPR720 would not work in patients with refractory disease. Again, there is no cross resistance with existing robotics [ph], but it’s just a strategy that Spero has adopted again to pursuit development in first – for first line treatment first.
Operator: This concludes the question-and-answer session. I would like to turn the conference back over to Mr. Shukla for any closing remarks. Please go ahead.
Sath Shukla: Thanks operator. We appreciated the opportunity to provide an update on our recent progress and look forward to the continued advancement of our clinical programs. Thanks to everybody listening and for your participation today. Have a nice evening.
Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.
